As your Financial Advisor, I can help you define and strive to meet your goals by delivering a vast array of resources to you in the way that is most appropriate for how you invest and what you want to achieve. Working together I can help you to preserve and grow your wealth. You will have access to some of the world’s most seasoned and respected investment professionals, a premier trading and execution platform and a full spectrum of investment choices.
- Emerson, NJ Recreation Department Director
- Jack Martin Fund for Mount Sinai Hospital
New York, NY
- Emerson Youth Sports Association
- Officer Young Couples Club JCC
- Asset Management
- Access to Lending Services
- Philanthropic Services
- Art Advisory
- Trust Services and Accounting
- Estate Planning Strategies
- Family Consulting
- Alternative Investments
- Wealth Management
- Endowments and Foundations
- Fixed Income
- Retirement Planning
- Executive Benefit Services
- Education Planning
- Exchange Traded Funds
- 401(k) Rollovers
- Certificates of Deposit
- BA - 1986
New Brunswick, NJ
- Financial Planning Specialist Designation
- Series 7 - General Securities License
- Series 63 - Uniform Exam
- Series 65 - Investment Advisory Agent License
- Series 3 - Commodities
- Chairman's Council - Smith Barney
- President's Council - Smith Barney
- Century Council - Smith Barney
- 20 Year Loyal Service Award - Smith Barney
- Graduated Honors - Rutgers College
- Present: Morgan Stanley*
Senior Vice President
Financial Planning Specialist
Investment Management Specialist/
New York, NY
- 1988: Standard Poor's
Equity Research Analyst
New York, NY
Please call or email me for a complimentary portfolio review.
See September On the Markets from the Global Investment Committee featuring
• “Attitude Matters” Michael Wilson, chief investment officer of Morgan Stanley Wealth Management, says few investors believe the world can overcome the obstacles it faces. And this attitude, he adds, prevents them from seeing and acting on positive developments.
• “Say What? Biotech Is Cheaper Than Pharma?” Historically, US biotechnology stocks have traded at a big premium to big European and US pharmaceutical companies because of their much faster growth rate. But now, for a variety of reasons, biotech is on a par with big pharma or even cheaper. Adam Parker, chief US equity strategist for Morgan Stanley & Co., explains how this anomalous behavior came to be.
• "Higher Oil Prices and Reforms Give MLPs a Lift" Last year, midstream master limited partnerships faced a perfect storm of lower commodity prices, falling US hydrocarbon production and rising interest rates—and the results were brutal. Now, attractive valuation, higher energy prices and industry reforms give MLPs a brighter outlook, writes Vijay Chandar, market strategist for Morgan Stanley Wealth Management.
• Plus, look for more on equities, fixed income and a Q&A with Morgan Stanley Investment Management’s Ruchir Sharma about the changing nature of the emerging markets.
Check the background of our Firm and Investment Professionals on FINRA's BrokerCheck.
Securities Agent: AL, CA, CT, DC, FL, GA, IL, MA, MD, MI, NC, NJ, NV, NY, OH, PA, TX, UT, VA, VI; General Securities Representative; Investment Advisor Representative; Transactional Futures/Commodities; Managed Futures
On the Markets